Entrada Therapeutics, Inc. Common Stock
TRDA US29384C1080
Entrada Therapeutics Inc clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Its pipeline includes solutions for Neuromuscular Disease, Beyond Neuromuscular, and Platform Expansion.
Annual Performance 1
| 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -29% | -20% | 12% | 14% | 0% |
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
| Person | Price | Shares | Total | Published | Completed |
|---|---|---|---|---|---|
| Parmar Kush O |
7.50 USD |
6,935 Sold |
52,026 USD |
09/07/2025 | 09/07/2025 |
| Parmar Kush O |
7.50 USD |
20,065 Sold |
150,528 USD |
09/07/2025 | 09/07/2025 |
| Parmar Kush O |
7.12 USD |
18,578 Sold |
132,324 USD |
27/06/2025 | 01/07/2025 |
| Parmar Kush O |
7.12 USD |
6,422 Sold |
45,741 USD |
27/06/2025 | 01/07/2025 |
| Parmar Kush O |
6.81 USD |
6,422 Sold |
43,751 USD |
27/06/2025 | 30/06/2025 |
| Parmar Kush O |
6.81 USD |
18,578 Sold |
126,566 USD |
27/06/2025 | 30/06/2025 |
| Parmar Kush O |
6.91 USD |
19,265 Sold |
133,121 USD |
27/06/2025 | 27/06/2025 |
| Parmar Kush O |
6.91 USD |
55,735 Sold |
385,129 USD |
27/06/2025 | 27/06/2025 |
| Wentworth Kory James CFO |
10.67 USD |
1,784 Sold |
19,035 USD |
17/03/2025 | 17/03/2025 |
| Sethuraman Natarajan PR |
20.15 USD |
11,703 Sold |
235,786 USD |
29/11/2024 | 03/12/2024 |